Novartis has announced an agreement to acquire Tourmaline Bio.

诺华宣布达成收购Tourmaline Bio的协议。

Tourmaline is developing pacibekitug, an anti-IL-6 monoclonal antibody (mAb) for the treatment of atherosclerotic cardiovascular disease.

Tourmaline公司正在开发pacibekitug，一种用于治疗动脉粥样硬化性心血管疾病的抗IL-6单克隆抗体（mAb）。

The addition of pacibekitug is expected to complement Novartis’ cardiovascular portfolio by targeting IL-6, a key cytokine that drives systemic inflammation. Inflammation is recognised as a major contributor to cardiovascular disease, yet no widely adopted anti-inflammatory therapies currently exist to reduce cardiovascular risk..

预计 pacibekitug 的加入将通过靶向白细胞介素-6（IL-6）这一驱动全身炎症的关键细胞因子，补充诺华的心血管产品组合。炎症被认为是心血管疾病的主要诱因，但目前尚无广泛采用的抗炎疗法来降低心血管风险。

Pacibekitug is designed as an investigational IgG2 human monoclonal antibody that binds with high affinity to IL-6. The Phase 2 TRANQUILITY 90-day study, released in May 2025, showed significant reductions in median high-sensitivity C-reactive protein (hs-CRP) levels. Results demonstrated an 85% reduction at a monthly dose of 15 mg and an 86% reduction at a quarterly dose of 50 mg.

Pacibekitug是一种研究性IgG2人类单克隆抗体，能够以高亲和力结合IL-6。2025年5月发布的二期TRANQUILITY 90天研究表明，高灵敏度C反应蛋白（hs-CRP）的中位水平显著降低。结果显示，每月15毫克剂量下减少了85%，每季度50毫克剂量下减少了86%。

Safety outcomes were comparable to placebo, highlighting the therapy’s potential as a convenient option with quarterly administration..

安全性结果与安慰剂相当，突显了该疗法作为一种每季度给药一次的便捷选择的潜力。

Through this acquisition, Novartis will secure a Phase 3-ready asset to support its cardiovascular strategy and address residual inflammatory risk in ASCVD. The company continues to focus on developing innovative treatments in areas of high unmet need, while also advancing technologies such as its xRNA platform and pursuing solutions for genetically driven cardiovascular conditions and common heart diseases, including atrial fibrillation..

通过此次收购，诺华将获得一款准备进入三期临床试验的资产，以支持其心血管战略，并解决动脉粥样硬化性心血管疾病（ASCVD）中的残留炎症风险。公司继续专注于在高度未满足需求的领域开发创新疗法，同时推进其xRNA平台等技术，并寻求针对基因驱动的心血管疾病和常见心脏疾病（包括心房颤动）的解决方案。

For more than four decades, Novartis has played a leading role in cardiovascular care and remains committed to tackling the most pressing challenges in this field.

四十多年来，诺华一直在心血管护理领域发挥着主导作用，并且仍然致力于应对该领域最紧迫的挑战。

Source: novartis.com

来源：novartis.com